Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

The purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.

Trial Details

NCT ID
NCT04513028
Phase
NA
Sponsor
Kelly McMasters
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Beta-Glucan
Locations (sample)
  • Louisville, Kentucky, United States|38.25424,-85.75941

Key Eligibility Criteria

  • Any patients with suspected (clinical) or definitive (tissue) diagnosis of Stage III-IV melanoma starting or continuing adjuvant Pembrolizumab with…
  • Must be treatment naïve or have had treatment no less than 6 months prior to enrollment
  • 18 years or older
  • Must be able to take pills

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →